Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NW 301V

Next Previous
X
Search
Drug Profile

NW 301V

Alternative Names: NW-301V

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neowise Biotechnology
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Jun 2024 Wuhan Union Hospital and Neowise Biotechnology initiates enrolment in a phase I trial for Solid tumour (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (NCT06484556)
  • 08 Apr 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in China (Parenteral) (NCT06484790)
  • 31 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (Parenteral) (NCT06478251)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top